Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
72/435
Résultats pour
“diabetes mellitus”
-
Glycogenic hepatopathy. Review
### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
…less accurate in type 2 diabetes mellitus (T2DM). We aimed to compare…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
…in patients with type 2 diabetes mellitus (T2DM). All patients underwent routine…
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
…in patients with type 2 diabetes mellitus (T2DM). ### Research Design And Methods…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
…Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM…
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
…unselected patients with type 2 diabetes. ### Design, Setting And Participants Two hundred…
-
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
…Type-2 diabetes provides an interesting model for assessing liver steatosis. Clinico…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
…in patients with type 2 diabetes mellitus (T2DM). **Methods**: This single-center…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
…the pandemic of type 2 diabetes. Here, the authors aimed to assess…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
…in individuals with type 2 diabetes (T2D). The primary objective of the…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication
…in individuals with type 2 diabetes (T2D) remains unclear. This study aimed…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
…in patients with type 2 diabetes mellitus (T2DM) is the prediction of…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
…diabetes. ### Methods A total of 179 people with Type 2 diabetes were…
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
…patients without T2-diabetes. When individual data are not available, adjusted-AUROCs…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
…including participants with type 2 diabetes and/or obesity and MASLD with…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
…alcohol consumption, and type 2 diabetes mellitus. ### Conclusions The results showed that…
-
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
…0.0001), and prevalence of diabetes mellitus (3% [0-12] vs 21…
-
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
…with or without type 2 diabetes mellitus (T2DM), alpha-2 macroglobulin (A2M…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…In type-2 diabetes, FibroTest predicted cardiovascular events and improved the Framingham…
-
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…
-
The non-invasive assessment of hepatic fibrosis. Review
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
…metabolic risk factors such as diabetes mellitus, dyslipidemia, and obesity. The MCV…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
…286 outpatients with type 2 diabetes, and in six previously published databases…
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
…in patients with type 2 diabetes (T2D) using the intention-to-diagnose…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
### Aim We evaluated the association between two medications that alter bioavailable androgen…
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
…The percent of patients with overweight, obesity, diabetes, hypertension, and dyslipidemia were…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
### Background Medical comorbidities and functional status limitations are determinants of mortality in…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
…Concomitantly, significant improvements in triglycerides, ALT, diabetes markers and adiponectin were observed…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
…52.5% with F4 NASH, 40% male, 72% with type 2 diabetes…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
…according to gender, presence of diabetes and between the 3 cohorts. ### Conclusion…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
### Background Mortality related to complications of cirrhosis is increasing in patients with…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
### Aim To compare noninvasive methods presently used for steatosis detection and quantification…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
…alcohol use, or type 2 diabetes, reported higher prevalence of advanced liver…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
…Complicated syndromes often accompanied by obesity and diabetes makes no standard treatment…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Acute hepatitis C virus infection remains a major health concern in human…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
### Background This prospective, monocentric study was designed to assess the efficacy of…
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
### Aim To assess the performance of several non-invasive markers and of…
-
Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
### Background Liver biopsy is an imperfect gold standard for assessing the disease…
-
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
### Background & Aims Most liver transplant centres have discontinued the practice of protocol…
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
…aspartate aminotransferase/alanine aminotransferase ratio, diabetes score (BARD score), FibroMeter, FibroTest, enhanced…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.